What is ROE for Vanda Pharmaceuticals Inc in the forth quarter 2023?
Vanda Pharmaceuticals Inc achieved a return on average equity (ROE) of
0.46 % in its forth quarter 2023, this is above VNDA's average return on equity of -3.41%.
Vanda Pharmaceuticals Inc shareholder's equity over the 12 months ending in its forth quarter 2023 are valued at $541 million
ROE decreased relative to the period ending , due to the decline in net income.
Within the
Major Pharmaceutical Preparations industry 34 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to
1575, from total ROE ranking in the third quarter 2023 at
1996.
What is ROE?